High-level production of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in high-density cultivation of recombinant Escherichia coli using a combined feeding strategy

被引：34
|
作者：
Shen, YL [1 ]
Zhang, Y [1 ]
Sun, AY [1 ]
Xia, XX [1 ]
Wei, DZ [1 ]
Yang, SL [1 ]
机构：
[1] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China
来源：
BIOTECHNOLOGY LETTERS | 2004年 / 26卷 / 12期
基金：
国家高技术研究发展计划(863计划);
关键词：
combined feeding strategy; Escherichia coli; fed-batch; high-cell-density cultivation; TRAIL;
D O I：
10.1023/B:BILE.0000030043.84226.ac
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Recombinant Escherichia coli strain C600/pBV-TRAIL (encoding for 114-281 amino acids of TRAIL's soluble fragment) produced a recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL). Using a combined strategy of exponential feeding and pH-stat feeding, high concentrations of biomass (65 g dry wt l(-1)) and active soluble TRAIL (1.4 g l(-1)) were obtained within 30 h. The accumulation of acetate, which usually occurs during the process of high-density culture of Escherichia coli and especially in the induction stage of protein synthesis, was avoided.
引用
收藏
页码：981 / 984
页数：4
相关论文
共 38 条
  • [31] RETRACTED: Resistance to apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines (Retracted Article. See vol 85, pg 1416, 2011)
    Matsuda, T
    Almasan, A
    Tomita, M
    Uchihara, J
    Masuda, M
    Ohshiro, K
    Takasu, N
    Yagita, H
    Ohta, T
    Mori, N
    JOURNAL OF VIROLOGY, 2005, 79 (03) : 1367 - 1378
  • [32] Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein
    Frese, S
    Brunner, T
    Gugger, M
    Uduehi, A
    Schmid, RA
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (01): : 168 - 174
  • [33] Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
    Ouyang, Xuenong
    Shi, Meiqi
    Jie, Fangwei
    Bai, Yuxian
    Shen, Peng
    Yu, Zhuang
    Wang, Xiuwen
    Huang, Cheng
    Tao, Min
    Wang, Zhehai
    Xie, Conghua
    Wu, Qi
    Shu, Yongqian
    Han, Baohui
    Zhang, Fengchun
    Zhang, Yiping
    Hu, Chunhong
    Ma, Xitao
    Liang, Yongjie
    Wang, Anlan
    Lu, Bing
    Shi, Yi
    Chen, Jinfei
    Zhuang, Zhixiang
    Wang, Jiejun
    Huang, Jianjin
    Wang, Changhui
    Bai, Chunxue
    Zhou, Xin
    Li, Qiang
    Chen, Feng
    Yu, Hao
    Feng, Jifeng
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 315 - 322
  • [34] Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
    Xuenong Ouyang
    Meiqi Shi
    Fangwei Jie
    Yuxian Bai
    Peng Shen
    Zhuang Yu
    Xiuwen Wang
    Cheng Huang
    Min Tao
    Zhehai Wang
    Conghua Xie
    Qi Wu
    Yongqian Shu
    Baohui Han
    Fengchun Zhang
    Yiping Zhang
    Chunhong Hu
    Xitao Ma
    Yongjie Liang
    Anlan Wang
    Bing Lu
    Yi Shi
    Jinfei Chen
    Zhixiang Zhuang
    Jiejun Wang
    Jianjin Huang
    Changhui Wang
    Chunxue Bai
    Xin Zhou
    Qiang Li
    Feng Chen
    Hao Yu
    Jifeng Feng
    Investigational New Drugs, 2018, 36 : 315 - 322
  • [35] A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Δ12,14 prostaglandin J2 production
    Hasegawa, Hiroo
    Yamada, Yasuaki
    Komiyama, Kanki
    Hayashi, Masahiko
    Ishibashi, Masami
    Sunazuka, Toshiaki
    Izuhara, Takeshi
    Sugahara, Kazuyuki
    Tsuruda, Kazuto
    Masuda, Masato
    Takasu, Nobuyuki
    Tsukasaki, Kunihiro
    Tomonaga, Masao
    Kamihira, Shimeru
    BLOOD, 2007, 110 (05) : 1664 - 1674
  • [36] Cotreatment with STI-571 Enhances Tumor Necrosis Factor α-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)-induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells (Expression of Concern of Vol 7, Pg 350, 2001)
    Nimmanapalli, Ramadevi
    Porosnicu, Mercedes
    Nguyen, Diep
    Worthington, Elizabeth
    O'Bryan, Erica
    Perkins, Charles
    Bhalla, Kapil
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 4195 - 4195
  • [37] Cotreatment with STI-571 enhances tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL or Apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells (Publication with Expression of Concern. See vol. 25, pg. 4195, 2019)
    Nimmanapalli, R
    Porosnicu, M
    Nguyen, D
    Worthington, E
    O'Bryan, E
    Perkins, C
    Bhalla, K
    CLINICAL CANCER RESEARCH, 2001, 7 (02) : 350 - 357
  • [38] Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-κB via inhibition of the prosurvival akt signaling pathway
    Deeb, Dorrah
    Jiang, Hao
    Gao, Xiaohua
    Al-Holou, Shaza
    Danyluk, Andrew L.
    Dulchavsky, Scott A.
    Gautam, Subhash C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (02): : 616 - 625
1234